March 21, 2023
GW Pharmaceuticals investors urged a California federal judge on Monday to grant preliminary approval to a $7.75 million settlement that ends their claims the British company misled shareholders to push through its $7.2 billion sale to Ireland-based Jazz Pharmaceuticals, calling it an "excellent" result.
June 06, 2022
GW Pharmaceuticals has asked a California federal judge to toss a proposed securities class action alleging the company misled investors to achieve a $7.2 billion acquisition deal, arguing that the purportedly misleading statements at issue were forward-looking and protected by cautionary language.
January 19, 2022
A California federal judge has appointed Monteverde & Associates and Kahn Swick & Foti as co-lead counsel of a proposed securities class action against GW Pharmaceuticals over claims that it misled investors to achieve a $7.2 billion acquisition deal with Ireland-based Jazz Pharmaceuticals.
August 04, 2021
Monteverde & Associates and Kahn Swick & Foti have asked a California federal judge to appoint them co-lead counsel of a proposed securities class action against GW Pharmaceuticals over claims that the cannabinoid-derived treatment manufacturer misled investors to achieve a $7.2 billion acquisition deal with Ireland-based Jazz Pharmaceuticals.